Evidence map›Paper›PMID 42240332›Full record

ArticleAntimicrobial agents and chemotherapy2026

Manogepix demonstrates potent

Nathan P Wiederhold, Hoja P Patterson, Carmita Sanders, Connie Canete-Gibas

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nathan P WiederholdFungus Testing Laboratory, Department of Pathology and Laboratory Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.ORCID 0000-0002-2225-5122
Hoja P PattersonFungus Testing Laboratory, Department of Pathology and Laboratory Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Carmita SandersFungus Testing Laboratory, Department of Pathology and Laboratory Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Connie Canete-GibasFungus Testing Laboratory, Department of Pathology and Laboratory Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.

Funding

Basilea Pharmaceutica
6 · The paper itself

Abstract

Manogepix, the active moiety of the prodrug fosmanogepix, is a novel investigational agent in clinical trials that inhibits Gwt1, depleting glycosylphosphatidylinositol (GPI)-anchored mannoproteins critical for fungal cell wall integrity. It has potent broad-spectrum antifungal activity, including against fungi that are often resistant to clinically available antifungals (e.g.,

Indexed as

Antifungal AgentsAscomycotaAspergillusCoccidioidesEurotialesScopulariopsisAmphotericin BCaspofunginDrug Resistance, FungalEchinocandinsFluconazoleHypocrealesItraconazoleLipopeptidesMicrobial Sensitivity TestsNitrilesAmphotericin BAntifungal AgentsCaspofunginEchinocandinsFluconazoleisavuconazoleItraconazoleLipopeptidesNitrilesposaconazolePyridinesTriazolesantifungal activityfilamentous fungimanogepix

Identifiers

PMID42240332
PMCPMC13321795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.